MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 13, 2007; DOI: 10.1124/mol.107.040204


0026-895X/08/7302-387-398$20.00
Mol Pharmacol 73:387-398, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.040204v1
73/2/387    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Evans, B. R.
Right arrow Articles by Hahn, M. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, B. R.
Right arrow Articles by Hahn, M. E.

Repression of Aryl Hydrocarbon Receptor (AHR) Signaling by AHR Repressor: Role of DNA Binding and Competition for AHR Nuclear Translocator

Brad R. Evans1, Sibel I. Karchner, Lenka L. Allan, Richard S. Pollenz, Robert L. Tanguay, Matthew J. Jenny, David H. Sherr, and Mark E. Hahn

Department of Biology, Woods Hole Oceanographic Institution, Woods Hole, Massachusetts (B.R.E., S.I.K., M.J.J., M.E.H.); Department of Biology, Boston University, Boston, Massachusetts (B.R.E.); Departments of Environmental Health (L.L.A., D.H.S.) and Microbiology (L.L.A.), Boston University School of Public Health, Boston, Massachusetts; Department of Biology, University of South Florida, Tampa, Florida (R.S.P); and Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon (R.L.T)

Activation of the aryl hydrocarbon receptor (AHR) by 2,3,7,8-tetrachlorodibenzo-p-dioxin causes altered gene expression and toxicity. The AHR repressor (AHRR) inhibits AHR signaling through a proposed mechanism involving competition with AHR for dimerization with AHR nuclear translocator (ARNT) and binding to AHR-responsive enhancer elements (AHREs). We sought to delineate the relative roles of competition for ARNT and AHREs in the mechanism of repression. In transient transfections in which AHR2-dependent transactivation was repressed by AHRR1 or AHRR2, increasing ARNT expression failed to reverse the repression, suggesting that AHRR inhibition of AHR signaling does not occur through sequestration of ARNT. An AHRR1 point mutant (AHRR1-Y9F) that could not bind to AHREs but that retained its nuclear localization was only slightly reduced in its ability to repress AHR2, demonstrating that AHRR repression does not occur solely through competition for AHREs. When both proposed mechanisms were blocked (AHRR1-Y9F plus excess ARNT), AHRR remained functional. AHRR1 neither blocked AHR nuclear translocation nor reduced the levels of AHR2 protein. Experiments using AHRR1 C-terminal deletion mutants showed that amino acids 270 to 550 are dispensable for repression. These results demonstrate that repression of AHR transactivation by AHRR involves the N-terminal portion of AHRR; does not involve competition for ARNT; and does not require binding to AHREs, although AHRE binding can contribute to the repression. We propose a mechanism of AHRR action involving "transrepression" of AHR signaling through protein-protein interactions rather than by inhibition of the formation or DNA binding of the AHR-ARNT complex.


Received July 19, 2007; accepted November 13, 2007

Address correspondence to: Dr. Mark E. Hahn, Department of Biology, MS#32, Woods Hole Oceanographic Institution, Woods Hole, MA 02543. E-mail: mhahn{at}whoi.edu.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics